PHARMA 40 2007 Bill and Melinda Gates, co-chairs, the Gates Foundation

As co-chairs of the Bill & Melinda Gates Foundation, Bill Foundation’s global health programme, said: ‘The and Melinda Gates have control of a fund of $31.9 billion. pharmaceutical industry plays a huge role in improving One of the foundation’s core missions is to tackle deadly global health, and we are proud to support several diseases such as malaria and tuberculosis. With this kind public-private partnerships working with industry. The of spending power and their determination to drive up pipeline of new drugs and vaccines for the developing global healthcare provision, the Gates’ influence on the world is stronger than before.’ pharma industry is unquestionable. Bill began his philanthropic efforts in earnest in 1994, ‘The Gates have largely abandoned their commercial when he created the William H Gates Foundation, which ventures to run their foundation, which is dedicated to focused on global health. Three years later, he and Melinda research aimed at eliminating serious infectious diseases,’ created the Gates Library Foundation, which worked to commented one of our judges. ‘Their example has moved bring public access computers with internet connections others with substantial wealth to follow their example. to public libraries in the US. The two groups merged in 1hence they are a powerful force for good.’ 2000 to form the Bill & Melinda Gates Foundation. The Gates meet with local, national, and international Joining Microsoft Corporation in 1987, Melinda oversaw grantees and partners to further the foundation’s goal the development of many of Microsoft’s multimedia of improving equity around the world. They also use products. In 1996, she retired from her position as general their many public appearances to focus attention on manager of information products. Since then, she has these issues. Dr Tachi Yamada, president of the Gates directed her energies towards the non-profit world.

14 WorldPharmaceuticalFrontiersWorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net WorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net 15 Welcome to World Pharmaceutical Frontiers’ first Pharma 40 – a list of the most influential people in the industry, as judged by industry experts.

The Pharma 40 has been for accuracy, but because the billion, but does their position Next year’s Pharma 40 will, a great opportunity to top spot was such a surprise. at the top spot represent a I’m sure, make equally evaluate the figures who Who would have thought shift in the balance of power? compelling reading. Until have the biggest impact on philanthropists exert such Certainly, according to our then, do you think our judges our industry – and to see the a massive influence on the judges, bigger does not mean have got it right? Is anyone sheer scope of their different industry? Clearly, Bill and better. Pfizer CEO Jeffrey missing from the list? influences. But when the votes Melinda Gates are no ordinary Kindler ranks 19th on the list, Give us your feedback on the came in, we had to triple- philanthropists, controlling and only a handful of CEOs Pharma 40 on our website: check our figures – not just as they do a pot of $31.9 crack the top 10. www.worldpharmaceuticals.net

11 Professor Rolf Krebs, scientist Bill and Melinda Gates 1 Co-chairs, Bill & Melinda Gates Foundation 12 Roger L Williams, CEO, United States Pharmacopeia 13 David Brennan, CEO, AstraZeneca 14 Arthur Levinson, CEO, Genentech Daniel Vasella 2 MD, chairman and CEO, 15 Jean-Pierre Garnier, CEO, GSK 16 Israel Makov, president and CEO, Teva 17 Marvin Carruthers, professor, University of Colorado Andrew von Essenbach 3 Acting commissioner, US FDA 18 M Cass Wheeler, CEO, American Heart Association 19 Jeffrey Kindler, CEO, Pfizer 20 Sir Michael Rawlins, chairman, NICE Craig C Mello 21 Henri A Termeer, CEO, Genzyme 4 Professor, University of Massachusetts 22 Dr M Venkateswarlu, drugs controller general of India Andrew Z Fire 23 Frances M Visco, president, National Breast Cancer Coalition & Professor, Stanford School of Medicine 24 Senator Charles E Grassley, chairman, Senate Finance Committee 25 Dietmar Hopp, entrepreneur and co-founder, SAP Thomas Lönngren 26 Tejendra Khanna, chairman, Ranbaxy 5 Executive director, EMEA 27 Eliot Spitzer, governor of New York 28 Tony Clement, minister of health, Canada Craig Venter 29 Shao Mingli, commissioner of the State FDA, China

6 Former CEO, Accelerys 30 Nancy Pelosi, speaker, US House of Representatives 31 Anji Reddy, chairman, Dr Reddy’s Laboratories Arthur Higgins 32 Michael J Fox, founder, Michael J Fox Foundation 7 Chairman, Bayer Healthcare Executive 33 H Fred Mickleson, chairman, National Board of Directors, Committee American Cancer Society 34 Bernard Poussot, president and vice chairman, Wyeth 35 Jean-François Dehecq, chairman and CEO, Sanofi Aventis Christopher Lipinski Ex-senior research fellow, Pfizer 36 Ronald D Luff, director of anatomic clinical trials, 8 Quest Diagnostics 37 Richard Reichman, William Bonnez and Robert Rose University of Rochester Bill Clinton 9 Founder, Clinton Foundation 38 Ranjit Shahani, president, Organisation of Pharmaceutical Producers of India 39 Richard T Clark, CEO, Merck Ginger Graham 40 Pankaj Patel, chairman, Zydus Cadila 10 CEO, Amylin Pharmaceuticals

14 WorldPharmaceuticalFrontiersWorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net WorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net 15 2 3

Daniel Vasella Andrew C von Eschenbach

Daniel Vasella earns second place in the Pharma 40 as CEO of Andrew C von Eschenbach, MD, was sworn in as the 20th Novartis, one of the largest pharma companies in the world, commissioner of the US FDA in December 2006. He leads the US’s generating sales of $37 billion in 2006. In charge of the Swiss giant premier consumer protection and health agency and, as such, holds since 1996, Vasella should be used to appearing in such power lists; sway over regulated products that account for more than 20% of three years ago, Time magazine named him as one of its 100 most consumer spending. influential people of 2004. As the former director of the National Cancer Institute (NCI), Vasella graduated with an MD from the in von Eschenbach is a nationally recognised urologic surgeon and 1979. After holding a number of medical positions in Switzerland, oncologist. His distinguished career as a leader in the fight against he joined Sandoz Pharmaceuticals Corporation in the US in cancer spans nearly three decades. Himself a cancer survivor, von 1988, where he became a member of the Sandoz Group Executive Eschenbach has had a major impact on the fight against cancer, Committee and CEO of Sandoz Pharma Ltd. which extends beyond the clinical and academic communities. He is a founding member of C-Change and was president-elect of the He has been the recipient of a number of awards, including the American Cancer Society. ’s Alumni Achievement Award, the Appeal of Conscience Award and the AJ Congress Humanitarian Award. Many organisations have recognised von Eschenbach for his In 2002, he was awarded an honorary doctorate by the University accomplishments, including the American Medical Writers of Basel. He has also been honoured with the Ordem Nacional Association, the American Urological Association, and the Uniformed do Cruzeiro do Sul (Brazil) and holds the rank of Chevalier in Services University of Health Sciences. In 2006, he was named one of the Ordre National de la Légion d’Honneur (France). Time magazine’s 100 most influential people.

Craig C Mello and Andrew Z Fire Craig Mello and Andrew Fire were jointly awarded the Nobel Prize in Physiology or Medicine in 2006 for their discovery of RNA interference – a breakthrough which has revolutionised the the study of gene function. Global pharma companies have been quick to exploit its ease of use, low cost and adaptability to high-throughput applications. 4 Mello was previously a postdoctoral fellow at the Fred Hutchinson Cancer Research Center in the laboratory of Dr James Priess. He joined the faculty of the University of Massachusetts Medical School in 1994. Fire conducted his initial work on gene silencing by double-stranded RNA at the Carnegie Institution. In 1989, he became an adjunct professor in the Johns Hopkins University department of biology and joined Stanford in 2003.

16 WorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net WorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net 17 5 8 Thomas Lönngren Christopher Lipinski

Thomas Lönngren was appointed executive director Dr Christopher Lipinski is best known as the author of the European Medicines Agency (EMEA) in January of the Rule Of Five, a simple algorithm for predicting 2001. The EMEA is responsible for the scientific drug compounds likely to show oral activity. He is evaluation of applications for European marketing currently a scientific adviser to Melior Discovery, a drug authorisation for medicinal products – about one-third of the new repurposing startup. He was adjunct senior research fellow at the Pfizer drugs introduced to the world market each year. Companies submit Global R&D Groton CT Laboratories until he retired in 2002. one single marketing authorisation application to the EMEA for the A consultant on drug-like properties, he serves on many scientific whole of Europe. advisory and journal editorial boards. In 2006, he received an honorary Lönngren qualified as a pharmacist from the University of Uppsala in law degree from the University of Dundee, and he is winner of the 2006 1976, where he was a lecturer until 1978. He served with the Swedish Society for Biomolecular Sciences Achievement Award. National Board of Health and Welfare from 1978 to 1990. From 1982 In 2005 he won the American Chemical Society’s E. B. Hershberg Award to 1984 he acted as senior pharmaceutical consultant for the Swedish for Important Discoveries in Medicinally Active Substances and in International Development Agency’s health cooperation programme 2004 won the the ACS Division of Medicinal Chemistry’s Division of in Vietnam. In 1990, he was appointed director of operations, Swedish Medicinal Chemistry Award. He is responsible for over 225 published Medical Products Agency, later becoming deputy director-general. articles and presentations and 17 issued US patents.

6 9 J Craig Venter Bill Clinton

Our judges ranked Dr J Craig Venter high in the Bill Clinton is perhaps another surprising face to Pharma 40 for his visionary contributions to genomic appear in our top 10, but as founder of the Clinton research, which have secured his place as one of the Foundation, he heads an organisation which campaigns Photo: © World Bank/Damian Milverton leading scientists of the 21st century. He is the founder strongly on global health issues. And as a former and president of the J Craig Venter Institute and the J Craig Venter president of the US, his public profile is second to none. Science Foundation, and the founder of the Institute for Genomic After leaving the White House, Clinton founded the Clinton Research. Research at the Venter Institute reflects his interest in Foundation, an organisation that campaigns on global health issues, advancing the science of genomics and in applying genomic advances to with an emphasis on HIV/AIDS; economic empowerment; leadership the world’s most vexing public health and environmental challenges. development and citizen service; and racial, ethnic and religious In 1998, he became the first president of Celera Genomics, where reconciliation. Following the 2002 Barcelona AIDS Conference, he sequenced the human genome using the whole genome shotgun he began the Clinton Foundation HIV/AIDS Initiative, which is technique, new mathematical algorithms and new automated DNA currently bringing life-saving treatment to over a quarter of a sequencing machines. million people around the world. His many awards include the 2002 Gairdner Foundation International Like Bill and Melinda Gates, our judges believe Clinton’s high-profile Award and the Ludwig Darmstaedter Prize. healthcare crusade is already changing the face of pharma.

7 10 Arthur J Higgins Ginger Graham

Bayer Healthcare is another global pharma giant Although she is soon to step down as CEO of Amylin, and Arthur J Higgins has been leading it since July Ginger Graham was picked by our judges for being a 2004. With a worldwide workforce of nearly 40,000 truly creative leader. Graham has been Amylin CEO in the fields of pharmaceuticals, animal health, since June 2006 and president since September 2003. consumer care and diabetes care, his influence on the global market She has served on the Audit Committee and the Nominating and is undeniable. Governance Committee, and has also held various positions with the Born in Scotland, Higgins studied at Scotland’s Strathclyde Guidant Corporation and Eli Lilly and Company. University, where he gained a Bachelor of Science in biochemistry. She serves on the board of directors of the Pharmaceutical Research He began his career in 1978 in the UK with Bristol-Myers. He has and Manufacturers of America, the California Healthcare Institute, the subsequently worked for Sandoz, Fisons, Abbott Laboratories and Harvard Business School Health Advisory Board, the Harvard Business Enzon Pharmaceuticals. School Dean’s Advisory Board, the Advisory Board for the Kellogg He is a member of the board of directors of the Pharmaceutical Center for Executive Women, the Advisory Board for the California Research and Manufacturers of America and a member of the Council on Science and Technology, and the University of California, Council of the International Federation of Pharmaceutical San Diego Health Sciences Advisory Board. She has an MBA from Manufacturers and Associations. Harvard University.

Have our judges got it right? Is anyone missing from the list? Give us your feedback on the Pharma 40 on our website www.worldpharmaceuticals.net

16 WorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net WorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net 17 11 Professor Rolf Krebs Genentech in 1980 as a senior approach for preparing DNA 21 Henri A Termeer, During a career spanning scientist holding various chips and large amounts of DNA. CEO, Genzyme 35 years, Professor Krebs has positions until he became Henri A Termeer was appointed served as president of the chairman and CEO in July CEO of one of the world’s 18 M Cass Wheeler, CEO, European Federation 1995. Levinson was appointed foremost biotech companies, American Heart Association of Pharmaceutical Industries a member of the board of Genzyme Corporation, in M Cass Wheeler has been and Associations from 1996 to directors that same year and 1985. Under his leadership, CEO of the one of the US’s 1998 and as president of the was named chairman of the Genzyme has grown into largest campaigning health International Federation of board in 1999. one of the world’s leading groups since October 1997. Pharmaceutical Manufacturers biotechnology companies. Under his leadership, the Association from 2000 to 15 Jean-Pierre Garnier, CEO, AHA merged its 56 individual 2002. He is responsible for the GlaxoSmithKline state and metropolitan development of a large number 22 Dr M Venkateswarlu, drugs affiliates into 12 regional of pharmaceutical products, JP Garnier assumed this role in controller general of India affiliates and adopted a has served on many advisory January 2001 with the merger As DCGI, Dr Venkateswarlu single corporate structure. boards and committees, and has of SmithKline Beecham and controls access to the Indian contributed to over 30 books. Glaxo Wellcome. He joined market, which is seeing massive SmithKline Beecham in growth and interest from major 1990 as president of its 19 Jeffrey Kindler, CEO, Pfizer pharma companies. 12 Roger L Williams, CEO, United pharmaceutical business Jeffrey Kindler became chairman States Pharmacopeia (USP) in North America and was and CEO of Pfizer, the Roger L Williams, MD, has been chairman of pharmaceuticals world’s largest research-based 23 Frances M Visco, president, the executive vice president and from 1994 until 1995. pharmaceutical company National Breast Cancer Coalition CEO of the USP since April in 2006. In his previous Frances Visco is the first president 2000. He provides strategic role of vice chairman and of NBCC, and a member of its 16 Israel Makov, president and leadership for USP under the general counsel, he has led board of directors and executive CEO, Teva Pharmaceuticals direction of its Board of Trustees. Pfizer’s worldwide legal, committee. In 1993, President He also serves as chairman Israel Makov has been the compliance, communications, Clinton appointed her as one of the Council of Experts, president and CEO of Teva government relations, of three members of the USP’s scientific body, which since April 2002. Makov is corporate citizenship, President’s Cancer Panel, and continuously revises the USP one of the founders of the policy development and she was the first consumer to and National Formulary. Israel National Nanotechnology global seciruty groups. chair the Integration Panel of Initiative. He has also been the Department of Defense a director of Bank Hapoalim Peer-Review Breast Cancer 13 David Brennan, CEO, since October 2002, and a 20 Sir Michael Rawlins, Research Program. AstraZeneca director of Ramot at Tel Aviv chairman, National Institute for David Brennan is an executive University since 2001. Clinical Excellence (NICE) director of AstraZeneca plc, Sir Michael Rawlins has been 24 Senator Charles E and a member of the executive chairman of NICE since its Grassley (Iowa) board of the Pharmaceutical 17 Marvin Caruthers, University formation in 1999. He is also As chairman of the Senate Research and Manufacturers of Colorado chairman of the Advisory Finance Committee, Grassley of America. He is also honorary The methodologies that are Council on the Misuse of has considerable influence board member of the US CEO currently used for chemically Drugs, an honorary professor over the shape and scope of Roundtable on Cancer. synthesising DNA were at the London School of key quality-of-life issues, originally developed in Hygiene and Tropical including Medicare and Professor Caruthers’ laboratory Medicine, University of Medicaid, affecting US 14 Arthur Levinson, CEO, almost 20 years ago. His London, and emeritus citizens. He has also been Genentech research has also pioneered professor at the University a major campaigner on Arthur Levinson joined a two-step DNA synthesis of Newcastle upon Tyne. pharmaceutical reform.

1 2 3 Judging panel 1 Michael A Santoro is an associate professor in Pharma 40 candidates were the business environment drawn from your suggestions department at the Rutgers on our website as well as Business School in Newark, nominations from pharma New Jersey in the US, and industry experts. From a 4 5 6 a faculty member of the shortlist, each judge ranked Rutgers Center for Global the names independently Change and Governance. and from their decisions we compiled the final list. Here, 2 Agnes V Klein, MD, DPH we profile our judges, with is director of the Centre thanks to each of them. for the Evaluation of

18 WorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net WorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net 19 25 Dietmar Hopp, among pharma companies has health campaigning 37 Richard Reichman, MD, German billionaire piqued and his influence on the organisations, for more William Bonnez, MD and The co-founder of German industry is likely to grow in the than 30 years, serving as Robert Rose, PhD, University software company SAP has forthcoming years. chair at the local and of Rochester invested millions in biotech national levels, including Richard Reichman is and sees the sector as one with chairman of the board of professor of medicine 3030 Nancy Pelosi, speaker of the great growth opportunities. the California Division. and of microbiology and House of Representatives immunology, William Bonnez The first woman in US is associate professor 26 Tejendra Khanna, history to lead a major party, of medicine and Robert chairman, Ranbaxy congresswoman Pelosi has Rose is associate professor Tejendra Khanna has been promised an agenda of driving 3434 Bernard Poussot, president of medicine and of chairman of Ranbaxy reform in healthcare in her and vice-chairman of Wyeth microbiology and immunology Laboratories Ltd since 1999. role as speaker of the House Bernard Poussot was elected at the University of Rochester. He is widely regarded as an of Representatives. COO and to the Wyeth They are the inventors expert in international trade board of directors in January of a vaccine to prevent and public administration. 2007 and was elected president 3131 Anji Reddy, chairman, and vice chairman in April human papillomaviruses, Dr Reddy’s Laboratories 2006. He is responsible a type of cancer that kills 27 Eliot Spitzer, Under Anji Reddy’s for overseeing Wyeth more than 250,000 women governor of New York chairmanship, Dr Reddy’s Pharmaceuticals, Wyeth around the world every year. Spitzer’s nomination to this Labs has been credited with Consumer Healthcare and list came in before his turning the Indian bulk drug Fort Dodge Animal Health. appointment as governor industry from dependence 3838 Ranjit Shahani, president, of New York, while he was on imports in the mid-1980s Organisation of Pharmaceutical still attorney general. His to self reliance in the mid-1990s producers of India (OPPI) position reflects the influence and into the export-oriented Ranjit Shahani is vice chairman 3535 Jean-François Dehecq, he has had on the industry industry that it is today. chairman and CEO, and managing director, and for helping to develop Sanofi-Aventis Novartis India Limited. He has been president of new disclosure policies 3232 Michael J Fox, actor Jean-François Dehecq was OPPI since 2001, and is in the pharmaceutical business. Michael J Fox was diagnosed selected for this list after he chairman of INTERPAT in India. with young-onset Parkinson’s created what is now one of 28 Tony Clement, minister Disease in 1991. Since 1998 the world’s largest drugmakers of health, Canada he has committed himself to through an aggressive 3939 Richard T Clark, CEO, Merck takeover of Aventis. There has been much focus on the campaign for increased Richard T Clark has held Canada’s health system and the Parkinson’s research and the a broad range of operating cost of drugs in the country. Michael J Fox Foundation and strategic positions during Tony Clement’s authority over is dedicated to ensuring the his tenure with Merck, a this area has been acknowledged development of a cure for 3636 Ronald D Luff, Quest world-leading research-driven in his ranking. Parkinson’s disease within Diagnostics pharmaceutical company. this decade. Ronald D Luff, MD, is 29 Shao Mingli, commissioner director of anatomic of the State FDA, China 3333 H Fred Mickleson, chairman of pathology for Quest Diagnostics’ 4040 Pankaj Patel, chairman, Shao Mingli oversees the the National Board of Directors, Teterboro laboratory. He Zydus Cadila standards set for the manufacture American Cancer Society also serves as clinical professor Pankaj Patel has guided Zydus and approval of drugs to one Fred Mickelson has been an and medical director of the Cadila down a path of accelerated of the world’s largest markets. active volunteer the American Program in Cytotechnology growth, from a Rs220 crore Although access to this market Cancer Society, one of the at Thomas Jefferson University company to a Rs870 crore group is limited, it is growing. Interest largest and most important in Philadelphia. with competence in healthcare.

Radiopharmaceuticals and Association of the British He is also chairman of leading provider of Biotherapeutic Products in Pharmaceutical Industry Molecular Staging, a market intelligence to the Biologics and Genetic and has more than 20 genomics and proteomics the pharmaceutical and Therapies Directorate. Her years’ experience in the company serving academic healthcare industries. special interests include healthcare industry, holding researchers and major the appropriate design of a range of senior leadership pharmaceutical companies. 5 Simon Hammett clinical trials and the various roles in the UK and is head of life sciences and complex ethical issues internationally. He is the 4 Clive Savage at Deloitte and Touche, attendant to the design and founder and president is director of corporate London. conduct of clinical trials. of New Medicine Partners, communications, EMEA, at an advisory firm assisting IMS Health. Operating in 6 James Drury 3 Dr Richard Barker pharmaceutical and more than 100 countries, James Drury is editor of is director general of the biotechnology companies. IMS Health is the world’s World Pharmaceutical Frontiers.

18 WorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net WorldPharmaceuticalFrontiers | www.worldpharmaceuticals.net 19